Physician profile
Alexander Merson
NPI 1194755983
$5,449.08
in general payments reported to CMS, 2019-2025
34 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $783 · 2021: $915 · 2022: $631 · 2023: $568 · 2024: $1,401 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591 · Travel and Lodging: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.81 |
| Travel and Lodging | $669.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $887.43 | 2019-2025 | Otezla, Repatha, Repatha |
| Globus Medical, INC. | $669.96 | 2024 | Reline |
| Abbvie INC. | $555.43 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $446.97 | 2019-2024 | Linzess |
| Lilly USA, LLC | $378.34 | 2019-2024 | Mounjaro, Jardiance |
| Aimmune Therapeutics, INC. | $297.24 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $284.59 | 2020-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $255.36 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $222.72 | 2021-2023 | |
| Esperion Therapeutics, INC. | $221.29 | 2020-2024 | Nexletol |
| Allergan, INC. | $177.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $115.96 | 2022-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $103.67 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $94.42 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.53 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $76.62 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.71 | 2019-2020 | |
| Pfizer INC. | $59.61 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $51.40 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.00 | 2021 | |
| Astellas Pharma US INC | $38.51 | 2020-2023 | Veozah |
| Shield Therapeutics INC | $36.05 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $35.68 | 2020 | |
| Amarin Pharma, INC. | $32.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.82 | 2020-2021 | |
| Genentech USA, INC. | $22.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.63 | 2025 | |
| Exact Sciences Corporation | $22.41 | 2024 | Cologuard Collection Kit |
| Shire North American Group INC | $19.15 | 2019 | |
| Linus Health, INC. | $18.24 | 2022 | |
| Merz North America, INC. | $18.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.18 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $16.06 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Merson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.